A comparison of @entity9229 and XXXX in the treatment of hyperprolactinemic @entity2588 . @entity9229 Comparative Study Group.

@entity1 @entity2847 @entity4089 @entity2013 @entity9229 @entity935 @entity4776 @entity976 @entity2588
BACKGROUND: @entity9229 is a long-acting @entity935 -agonist drug that suppresses prolactin secretion and restores gonadal function in @entity1 with hyperprolactinemic @entity2588 . We designed a study to compare its safety and efficacy with those of @entity2847 , which has been the standard therapy. METHODS: A total of 459 @entity1 with hyperprolactinemic @entity2588 were treated with either @entity9229 (0.5 to 1.0 mg twice weekly) or @entity2847 (2.5 to 5.0 mg twice daily), administered in a double-blind fashion for 8 weeks and subsequently in an open fashion for 16 weeks, during which adjustments in the dose were made according to the response. Of the 459 @entity1 , 279 had @entity2013 , 3 had @entity2013 , 1 had a @entity976 , 167 had idiopathic @entity4089 , and the remainder had an @entity4776 . Clinical and biochemical status was assessed at 2-week intervals for 8 weeks and monthly thereafter for a total of 6 months, with an additional assessment at 14 weeks. RESULTS: Stable normoprolactinemia was achieved in 186 of the 223 @entity1 treated with @entity9229 (83 percent) and 138 of the 236 @entity1 treated with @entity2847 (59 percent, P < 0.001). Seventy-two percent of the @entity1 treated with @entity9229 and 52 percent of those treated with @entity2847 had ovulatory cycles or became pregnant during treatment (P < 0.001). @entity2588 persisted in 7 percent of the @entity9229 -treated @entity1 and 16 percent of the @entity2847 -treated @entity1 . Adverse effects were recorded in 68 percent of the @entity1 taking @entity9229 and 78 percent of those taking @entity2847 (P = 0.03); 3 percent discontinued taking @entity9229 , and 12 percent stopped taking @entity2847 (P < 0.001) because of drug intolerance. Gastrointestinal symptoms were significantly less frequent, less severe, and shorter-lived in the @entity1 treated with @entity9229 . CONCLUSIONS: @entity9229 is more effective and better tolerated than @entity2847 in @entity1 with hyperprolactinemic @entity2588 .
